Recent Updates
Recently added Catalysts
KPTI Positive Sentiment Score: 70/100

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Monday, November 3, 2025 1 min read
Key Takeaway: Karyopharm Therapeutics Inc. announced the grant of 800 restricted stock units (RSUs) to a newly-hired employee under its 2022 Inducement Stock Incentive Plan, in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over a three-year period, with one-third of the shares vesting annually, contingent on the employee's ongoing service with the company. This action highlights Karyopharm's strategy to attract and retain talent in the competitive pharmaceutical industry.

Market Sentiment Analysis

POSITIVE FACTORS

  • Karyopharm is actively expanding its workforce by hiring new talent.
  • The RSU grant reflects the company's commitment to incentivizing employees.
  • The company's compliance with Nasdaq listing rules indicates stable governance.

Full Press Release Details

NEWTON, Mass., Nov. 3, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted an aggregate of 800 restricted stock units (RSUs) to one newly-hired employee. This RSU award was granted as of October 31, 2025 (the "Grant Date") pursuant to the Company's 2022 Inducement Stock Incentive Plan, as amended, as an inducement material to the new employee entering into employment with Karyopharm in accordance with Nasdaq Listing Rule 5635(c)(4).
The RSU award will vest over three years, with 33 1/3% of the shares underlying the RSU award vesting on each of the three consecutive anniversaries of the Grant Date. The vesting of the RSU award is subject to the employee's continued service as an employee of, or other service provider to, Karyopharm through the applicable vesting dates.
About Karyopharm Therapeutics
XPOVIO® and NEXPOVIO® are registered trademarks of Karyopharm Therapeutics Inc.
SOURCE Karyopharm Therapeutics Inc.

21 %

more press release views with

Frequently Asked Questions

What are RSUs awarded by Karyopharm?

Karyopharm awarded 800 restricted stock units (RSUs) to a newly-hired employee.

When were the RSUs granted at Karyopharm?

The RSUs were granted on October 31, 2025.

What is the vesting schedule for the RSUs?

The RSUs vest over three years at 33 1/3% annually.

What condition must be met for RSU vesting?

The employee must remain with Karyopharm through the vesting dates.

Which stock incentive plan is associated with the RSUs?

The RSUs are granted under the 2022 Inducement Stock Incentive Plan.

Tags: KPTI Viatris Investor Conferences Healthcare Karyopharm Therapeutics RSU grants Nasdaq rules inducement stock incentive
Last updated: Nov 3, 2025